Search Result

Results for "

gastrointestinal disorders

" in MedChemExpress (MCE) Product Catalog:

By Targets:	5-HT Receptor (3) Adrenergic Receptor (2) Apical Sodium-Dependent Bile Acid Transporter (1) Autophagy (7) Bacterial (8) Calcium Channel (1) Calmodulin (1) Cannabinoid Receptor (1) Cholecystokinin Receptor (3) Cytochrome P450 (1) Dopamine Receptor (3) Drug Metabolite (2) Endogenous Metabolite (1) GSK-3 (1) Histamine Receptor (1) Isotope-Labeled Compounds (2) LRRK2 (1) mAChR (1) Monoamine Oxidase (1) Motilin Receptor (2) Neurokinin Receptor (1) Phospholipase (6) Potassium Channel (1) Proton Pump (7) RET (2) SGLT (2)
By Research Areas:	Cancer (17) Cardiovascular Disease (4) Endocrinology (1) Infection (10) Inflammation/Immunology (12) Metabolic Disease (24) Neurological Disease (10)

By Targets:

5-HT Receptor (3)

Adrenergic Receptor (2)

Apical Sodium-Dependent Bile Acid Transporter (1)

Autophagy (7)

Bacterial (8)

Calcium Channel (1)

Calmodulin (1)

Cannabinoid Receptor (1)

Cholecystokinin Receptor (3)

Cytochrome P450 (1)

Dopamine Receptor (3)

Drug Metabolite (2)

Endogenous Metabolite (1)

GSK-3 (1)

Histamine Receptor (1)

Isotope-Labeled Compounds (2)

LRRK2 (1)

mAChR (1)

Monoamine Oxidase (1)

Motilin Receptor (2)

Neurokinin Receptor (1)

Phospholipase (6)

Potassium Channel (1)

Proton Pump (7)

RET (2)

SGLT (2)

By Research Areas:

Cancer (17)

Cardiovascular Disease (4)

Endocrinology (1)

Infection (10)

Inflammation/Immunology (12)

Metabolic Disease (24)

Neurological Disease (10)

Inhibitors & Agonists

Screening Libraries

Natural
Products

Isotope-Labeled Compounds

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-108283

Trepibutone AA 149; Supacal	Others	Inflammation/Immunology
Trepibutone (AA 149) increases secretion of bile and pancreatic juice, and accelerates flaccidity of the smooth muscle in the gastrointestinal tract. Trepibutone can be used for the research of cholecystitis and functional gastrointestinal disorders .

HY-145453

Propacetamol	Others	Inflammation/Immunology Cancer
Propacetamol is an analgesic agent. Propacetamol also is a precursor form of paracetamol. Propacetamol can be used in postoperative pain, acute trauma and gastrointestinal disorders .

HY-108292

Propacetamol hydrochloride	Others	Cancer
Propacetamol hydrochloride is an analgesic agent. Propacetamol hydrochloride also is a precursor form of paracetamol. Propacetamol hydrochloride can be used in postoperative pain, acute trauma and gastrointestinal disorders .

HY-B1613

Clebopride	Dopamine Receptor	Neurological Disease Metabolic Disease
Clebopride is a selective dopamine receptor antagonist. Clebopride can be used in the study of functional gastrointestinal disorders .

HY-108283R

Trepibutone (Standard)	Others	Inflammation/Immunology
Trepibutone (Standard) is the analytical standard of Trepibutone. This product is intended for research and analytical applications. Trepibutone (AA 149) increases secretion of bile and pancreatic juice, and accelerates flaccidity of the smooth muscle in the gastrointestinal tract. Trepibutone can be used for the research of cholecystitis and functional gastrointestinal disorders .

HY-147563

RET-IN-17	RET	Cancer
RET-IN-17 is a potent inhibitor of RET. RET-IN-17 has the potential for the research of pain associated with IBS and other gastrointestinal disorders and for the research of cancers with constitutive RET kinase activity (extracted from patent WO2016038552A1, compound 1) .

HY-B0189B

Mosapride citrate dihydrate TAK-370 citrate dihydrate; AS-4370 citrate dihydrate	5-HT Receptor Potassium Channel Cytochrome P450	Metabolic Disease
Mosapride (TAK-370) citrate dehydrate is a gastroprokinetic agent with 5-hydroxytryptamine₄ receptor agonist activity and has been widely used in the research of a variety of gastrointestinal disorders. Mosapride citrate dihydrate potently inhibits Kv4.3 in a concentration-dependent manner with IC₅₀ values of 15.2 μM . Mosapride citrate dihydrateselectively stimulates upper GI motility in vivo .

HY-108292R

Propacetamol hydrochloride (Standard)	Others	Cancer
Propacetamol (hydrochloride) (Standard) is the analytical standard of Propacetamol (hydrochloride). This product is intended for research and analytical applications. Propacetamol hydrochloride is an analgesic agent. Propacetamol hydrochloride also is a precursor form of paracetamol. Propacetamol hydrochloride can be used in postoperative pain, acute trauma and gastrointestinal disorders .

HY-145453R

Propacetamol (Standard)	Others	Inflammation/Immunology Cancer
Propacetamol (Standard) is the analytical standard of Propacetamol. This product is intended for research and analytical applications. Propacetamol is an analgesic agent. Propacetamol also is a precursor form of paracetamol. Propacetamol can be used in postoperative pain, acute trauma and gastrointestinal disorders .

HY-147564

RET-IN-18	RET	Neurological Disease Cancer
RET-IN-18 is a pyridone compound. is a potent inhibitor of RET. RET-IN-18 is a potent inhibitor of RET. RET-IN-18 has the potential for the research of diseases related to irritable bowel syndrome (IBS) and other gastrointestinal disorders, as well as cancers, and neurodegenerative diseases (extracted from patent WO2022017524A1, compound 1) .

HY-40294

Indazole	Monoamine Oxidase GSK-3 LRRK2	Cardiovascular Disease Neurological Disease Cancer
Indazole, also called isoindazole, a heterocyclic aromatic organic compound. Its derivatives display a broad variety of biological activities including anti-inflammatory, antibacterial, anti-HIV, antiarrhythmic, antifungal and antitumour properties. Indazole and its derivatives can be used for research of cancer, neurological disorders, cardiovascular diseases, gastrointestinal diseases .

HY-B1613A

Clebopride malate 1 Publications Verification	Dopamine Receptor	Neurological Disease Metabolic Disease
Clebopride malate is a dopamine antagonist used in the study of functional gastrointestinal disorders.

HY-U00382

Substance P Receptor Antagonist 1	Neurokinin Receptor	Neurological Disease Inflammation/Immunology
Substance P Receptor Antagonist 1 has the potential function in central nervous system disorders, respiratory, inflammatory diseases and gastrointestinal disorders.

HY-U00397

CB1 antagonist 1	Cannabinoid Receptor	Cardiovascular Disease Neurological Disease Metabolic Disease Inflammation/Immunology
CB1 antagonist 1 is an antagonist of CB1 receptor, used in the research of metabolic syndrome and obesity, neuroinflammatory disorders, cognitive disorders and psychosis, gastrointestinal disorders, and cardiovascular conditions.

HY-U00375

Gastrin/CCK antagonist 1	Cholecystokinin Receptor	Endocrinology
Gastrin/CCK antagonist 1 is an antagonist of gastrin/CCK, used for the research of gastrointestinal disorders.

HY-144401

DS-3801b	Motilin Receptor	Metabolic Disease
DS-3801b is a potent and non-macrolide agonist of GPR38. DS-3801b is expected to be novel gastrointestinal prokinetic agents for the research of functional gastrointestinal disorders such as gastroparesis and chronic constipation .

HY-103146

GR125487 sulfamate	5-HT Receptor	Neurological Disease
GR125487 sulfamate is an orally active and selective antagonist of 5-HT₄R. GR125487 sulfamate effectively blocks the cognition enhancing effect. GR125487 sulfamate can be used to study memory disorders, gastrointestinal disorders, mood disorders and urinary tract dysfunction .

HY-U00415

Benzamide Derivative 1	Dopamine Receptor mAChR	Neurological Disease
Benzamide Derivative 1 is a benzamide derivative from patent EP0213775A1, compound 18. Benzamide Derivative 1 may be useful in treatment of gastrointestinal disorders.

HY-B1667

Isopropamide iodide	Others	Metabolic Disease
Isopropamide iodide is a long-acting quaternary anticholinergic agent. Isopropamide iodide is used in peptic ulcer and other gastrointestinal disorders marked by hyperacidity and hypermotility .

HY-107642

MA-2029	Motilin Receptor	Metabolic Disease
MA-2029 is a selective, orally active, and competitive motilin receptor antagonist (IC₅₀=4.9 nM). MA-2029 is selective for the motilin receptor over various other receptors and ion channels. MA-2029 may be useful for gastrointestinal disorders associated with disturbed gastrointestinal motility .

HY-U00286

5-HT2A antagonist 1	5-HT Receptor	Cardiovascular Disease
5-HT2A antagonist 1 is a 5-HT2A antagonist extracted from patent US5728835A and JP 1007727. 5-HT2A antagonist 1 may be useful in treatment of gastrointestinal disorders circulatory disorders.

HY-B2175

Aspirin Aluminum Aluminum diacetylsalicylate	Others	Inflammation/Immunology
Aspirin Aluminum is a novel intermolecular compound which can inhibit gastrointestinal mucosal disorders induced by NSAIDs (non-steroidal anti-inflammatory agents) extracted from patent WO 2010064441 A1.

HY-148795

Ritivixibat	Apical Sodium-Dependent Bile Acid Transporter	Cardiovascular Disease Metabolic Disease
Ritivixibat is an inhibitor of ileal bile acid transporter (IBAT), as well as a bile acid modulator. Ritivixibat can be used for research of cardiovascular diseases, fatty acid metabolism and glucose utilization disorders, gastrointestinal diseases and liver diseases .

HY-N0584B

Anisodamine hydrochloride 6-Hydroxyhyoscyamine hydrochloride	Adrenergic Receptor	Inflammation/Immunology
Anisodamine hydrochloride is an anticholinergic and α1 adrenergic receptor antagonist. Anisodamine hydrochloride can be used for improving blood flow in circulatory disorders such as septic shock, Anisodamine hydrochloride displays a spectrum of pharmacological effects similar to Atropine (HY-B1205) and Sopolamine (HY-B2065) including inhibition of salivation, gastrointestinal and sweat secretion, gastrointestinal motility, respiratory secretion and urinary bladder contraction in vivo .

HY-B1667R

Isopropamide iodide (Standard)	Others	Metabolic Disease
Isopropamide (iodide) (Standard) is the analytical standard of Isopropamide (iodide). This product is intended for research and analytical applications. Isopropamide iodide is a long-acting quaternary anticholinergic agent. Isopropamide iodide is used in peptic ulcer and other gastrointestinal disorders marked by hyperacidity and hypermotility .

HY-122991

Prospasmine hydrochloride	Others	Neurological Disease
Prospasmine hydrochloride is an anticholinergic drug that has the activity of inhibiting glandular secretions and relaxing smooth muscles. Prospasmine hydrochloride is mainly used to inhibit certain types of gastrointestinal disorders. Prospasmine hydrochloride helps relieve pain caused by smooth muscle spasms. Prospasmine hydrochloride is also used as an anesthetic adjuvant in some cases .

HY-101225

8 Hydroxy PIPAT oxalate	Others	Inflammation/Immunology
8 Hydroxy PIPAT oxalate is a selective 5-HT1A receptor agonist that promotes the release of histamine from enteric mast cells. 8 Hydroxy PIPAT oxalate activates serotonergic signaling pathways, leading to the degranulation of mast cells in both guinea pig and human intestinal preparations. 8 Hydroxy PIPAT oxalate enhances the spontaneous release of histamine, which may contribute to the regulation of gastrointestinal functions. 8 Hydroxy PIPAT oxalate has potential implications for understanding and treating functional gastrointestinal disorders such as irritable bowel syndrome.

HY-135111

4-Desmethoxy Omeprazole	Drug Metabolite	Infection Metabolic Disease Cancer
4-Desmethoxy Omeprazole is the active metabolite of Omeprazole. Omeprazole, a proton pump inhibitor (PPI), is available for treatment of acid-related gastrointestinal disorders. Omeprazole shows competitive inhibition of CYP2C19 activity with a K_i of 2 to 6 μM . Omeprazole also inhibits growth of Gram-positive and Gram-negative bacteria .

HY-17638

Mizagliflozin 3 Publications Verification DSP-3235 free base; KGA-3235 free base; GSK-1614235 free base	SGLT	Metabolic Disease
Mizagliflozin (DSP-3235 free base) is a potent, orally active and selective SGLT1 inhibitor, with a K_i of 27 nM for human SGLT1. Mizagliflozin displays 303-fold selectivity over SGLT2. Mizagliflozin is used as an antidiabetic agent that can modify postprandial blood glucose excursion. Mizagliflozin also exhibits potential in the amelioration of chronic constipation .

HY-17638A

Mizagliflozin (sebacate) DSP-3235 (sebacate); KGA-3235 (sebacate); GSK-1614235 (sebacate)	SGLT	Neurological Disease
Mizagliflozin sebacate (DSP-3235 sebacate) is a sodium-glucose cotransporter inhibitor with activity in improving vascular cognitive impairment caused by small vessel disease. Mizagliflozin sebacate improves blood flow and reverses vascular cognitive impairment by inhibiting neuronal SGLT1 activity. Mizagliflozin sebacate also showed the ability to increase the survival rate of IL-1β-treated PC12HS cells. Mizagliflozin sebacate promotes improvements in spatial learning and memory caused by small vessel disease in mouse models .

HY-B0113S

Omeprazole-d₃ H 16868-d₃	Proton Pump Bacterial Autophagy	Infection Metabolic Disease Cancer
Omeprazole-d₃ is deuterium labeled Omeprazole. Omeprazole, a proton pump inhibitor (PPI), is available for treatment of acid-related gastrointestinal disorders. Omeprazole shows competitive inhibition of CYP2C19 activity with a Ki of 2 to 6 μM[1]. Omeprazole also inhibits growth of Gram-positive and Gram-negative bacteria[2].

HY-106301

Devazepide 3 Publications Verification L-364,718; MK-329	Cholecystokinin Receptor	Metabolic Disease
Devazepide (L-364,718) is a potent, competitive, selective and orally active nonpeptide antagonist of cholecystokinin (CCK) receptor, with IC₅₀s of 81 pM, 45 pM and 245 nM for rat pancreatic, bovine gallbladder and guinea pig brain CCK receptors, respectively. Devazepide (L-364,718) is effective for gastrointestinal disorders .

HY-B0113

Omeprazole 3 Publications Verification H 16868	Proton Pump Autophagy Bacterial Phospholipase	Infection Metabolic Disease Cancer
Omeprazole (H 16868), a proton pump inhibitor (PPI), is available for treatment of acid-related gastrointestinal disorders. Omeprazole shows competitive inhibition of CYP2C19 activity with a K_i of 2 to 6 μM . Omeprazole also inhibits growth of Gram-positive and Gram-negative bacteria .Omeprazole is a potent brain penetrant neutral sphingomyelinase (N-SMase) inhibitor (exosome inhibitor) .

HY-B0113A

Omeprazole sodium 3 Publications Verification H 16868 sodium	Proton Pump Autophagy Bacterial Phospholipase	Infection Metabolic Disease Cancer
Omeprazole sodium (H 16868 sodium), a proton pump inhibitor (PPI), is available for treatment of acid-related gastrointestinal disorders. Omeprazole sodium shows competitive inhibition of CYP2C19 activity with a K_i of 2 to 6 μM . Omeprazole sodium also inhibits growth of Gram-positive and Gram-negative bacteria . Omeprazole is a potent brain penetrant neutral sphingomyelinase (N-SMase) inhibitor (exosome inhibitor) .

HY-106301R

Devazepide (Standard)	Cholecystokinin Receptor	Metabolic Disease
Devazepide (Standard) is the analytical standard of Devazepide. This product is intended for research and analytical applications. Devazepide (L-364,718) is a potent, competitive, selective and orally active nonpeptide antagonist of cholecystokinin (CCK) receptor, with IC₅₀s of 81 pM, 45 pM and 245 nM for rat pancreatic, bovine gallbladder and guinea pig brain CCK receptors, respectively. Devazepide (L-364,718) is effective for gastrointestinal disorders .

HY-B0113R

Omeprazole (Standard)	Proton Pump Autophagy Bacterial Phospholipase	Infection Metabolic Disease Cancer
Omeprazole (Standard) is the analytical standard of Omeprazole. This product is intended for research and analytical applications. Omeprazole (H 16868), a proton pump inhibitor (PPI), is available for treatment of acid-related gastrointestinal disorders. Omeprazole shows competitive inhibition of CYP2C19 activity with a K_i of 2 to 6 μM . Omeprazole also inhibits growth of Gram-positive and Gram-negative bacteria .Omeprazole is a potent brain penetrant neutral sphingomyelinase (N-SMase) inhibitor (exosome inhibitor) .

HY-135111R

4-Desmethoxy Omeprazole (Standard)	Drug Metabolite	Infection Metabolic Disease Cancer
4-Desmethoxy Omeprazole (Standard) is the analytical standard of 4-Desmethoxy Omeprazole. This product is intended for research and analytical applications. 4-Desmethoxy Omeprazole is the active metabolite of Omeprazole. Omeprazole, a proton pump inhibitor (PPI), is available for treatment of acid-related gastrointestinal disorders. Omeprazole shows competitive inhibition of CYP2C19 activity with a Ki of 2 to 6 μM . Omeprazole also inhibits growth of Gram-positive and Gram-negative bacteria .

HY-B0113S1

Omeprazole-d3-1 H 16868-d₃-1	Proton Pump Autophagy Bacterial Phospholipase	Infection Metabolic Disease Cancer
Omeprazole-d₃-1 is the deuterium labeled Omeprazole. Omeprazole (H 16868), a proton pump inhibitor (PPI), is available for treatment of acid-related gastrointestinal disorders. Omeprazole shows competitive inhibition of CYP2C19 activity with a Ki of 2 to 6 μM[1]. Omeprazole also inhibits growth of Gram-positive and Gram-negative bacteria[2].Omeprazole is a potent brain penetrant neutral sphingomyelinase (N-SMase) inhibitor (exosome inhibitor)[3].

HY-N6948S

Linalyl acetate-d6	Isotope-Labeled Compounds	Inflammation/Immunology
Linalyl acetate-d₆ is deuterated labeled Omeprazole (HY-B0113). Omeprazole (H 16868), a proton pump inhibitor (PPI), is available for treatment of acid-related gastrointestinal disorders. Omeprazole shows competitive inhibition of CYP2C19 activity with a K_i of 2 to 6 μM . Omeprazole also inhibits growth of Gram-positive and Gram-negative bacteria .Omeprazole is a potent brain penetrant neutral sphingomyelinase (N-SMase) inhibitor (exosome inhibitor) .

HY-B0113S4

Omeprazole-d3 sodium H 16868-d₃ sodium	Autophagy Phospholipase Proton Pump Bacterial Isotope-Labeled Compounds	Infection Metabolic Disease Cancer
Omeprazole-d₃ sodium is deuterated labeled Omeprazole (HY-B0113). Omeprazole (H 16868), a proton pump inhibitor (PPI), is available for treatment of acid-related gastrointestinal disorders. Omeprazole shows competitive inhibition of CYP2C19 activity with a K_i of 2 to 6 μM . Omeprazole also inhibits growth of Gram-positive and Gram-negative bacteria .Omeprazole is a potent brain penetrant neutral sphingomyelinase (N-SMase) inhibitor (exosome inhibitor) .

HY-W153897

N-Methyltyramine	Adrenergic Receptor	Metabolic Disease
N-Methyltyramine is a protoalkaloid that can be isolated from various plant species. N-Methyltyramine is an α2-adrenoreceptor antagonist. N-Methyltyramine enhances appetite and digestion of foods by stimulating gastrin and pancreatic secretions. N-Methyltyramine can relax mouse small intestinal smooth muscle and inhibits small intestinal propulsion .

HY-B0113S3

Omeprazole-13CD3 H 16868-¹³C,d₃	Proton Pump Autophagy Bacterial Phospholipase	Infection Metabolic Disease Cancer
Omeprazole- ¹³C,d₃ is a ¹³C-labeled and deuterium labeled Omeprazole. Omeprazole (H 16868), a proton pump inhibitor (PPI), is available for treatment of acid-related gastrointestinal disorders. Omeprazole shows competitive inhibition of CYP2C19 activity with a Ki of 2 to 6 μM[1]. Omeprazole also inhibits growth of Gram-positive and Gram-negative bacteria[2].Omeprazole is a potent brain penetrant neutral sphingomyelinase (N-SMase) inhibitor (exosome inhibitor)[3].

HY-P2797

Chitinase, Serratia marcescens AMCase, Serratia marcescens	Bacterial	Metabolic Disease Inflammation/Immunology
Chitinase, Serratia marcescens (EC 3.2.1.14) has partial lysozyme activity and is widely found in bacteria, fungi, animals and some plants. Chitinase belongs to the glycosyl hydrolase family. Chitinase catalyzes chito-oligosaccharide hydrolysis. Chitinases also can serve as prognostic biomarkers of disease progression. Chitinase can be used in the research of pathogenesis of various human fibrotic and inflammatory disorders, particularly those of the lung (idiopathic pulmonary fibrosis, chronic obstructive pulmonary disease, sarcoidosis, and asthma) and the gastrointestinal tract (inflammatory bowel diseases (IBDs) and colon cancer) .

HY-N7503

Psoralenoside	Histamine Receptor Calcium Channel Calmodulin	Infection Metabolic Disease Cancer
Psoralenoside is a benzofuran glycoside from Psoralea corylifolia . Psoralenoside exhibits high binding affinities against histaminergic H₁, calmodulin, and voltage-gated L-type calcium channels (E-value≥-6.5 Kcal/mol) . Psoralenoside shows estrogen-like activity, osteoblastic proliferation accelerating activity, antitumor effects and antibacterial activity .

HY-15026

ATB 429	Endogenous Metabolite	Inflammation/Immunology
ATB-429, a novel H2S-releasing derivative of mesalamine, demonstrates significant anti-nociceptive and anti-inflammatory effects in models of irritable bowel syndrome (IBS). By releasing hydrogen sulfide (H2S), ATB-429 modulates colorectal distension-induced hypersensitivity in both healthy and postcolitic rats. It attenuates abdominal withdrawal responses and suppresses spinal c-Fos mRNA expression, indicating its potential to alleviate pain associated with gastrointestinal inflammation. Moreover, ATB-429 down-regulates colonic cyclooxygenase-2 and interleukin-1β mRNA expression, effects not observed with mesalamine alone. The mechanism involves ATP-sensitive K+ (KATP) channels, as evidenced by reversal of ATB-429's effects with glibenclamide. These findings suggest ATB-429 could offer therapeutic benefits for managing painful intestinal disorders linked to inflammation .

Cat. No.	Product Name

HY-L087

Anti-Obesity Compound Library

2,411 compounds

Obesity is widely recognized as the largest and fastest growing public health problem and is associated with numerous chronic disorders including osteoarthritis, obstructive sleep apnea, gallstones, fatty liver disease, reproductive and gastrointestinal cancers, dyslipidemia, hypertension, type 2 diabetes, heart failure, coronary artery disease, stroke, etc. Although obesity has long been associated with serious health issues, it has only recently been regarded as a disease in the sense of being a specific target for medical therapy. Obesity may be viewed as the dysregulation of two physiological functions, appetite regulation and energy metabolism, which combine to create disordered energy balance. Consequently, developing obesity treatments that target novel pathways is a growing focus for both biopharmaceutical industries.

MCE Anti-Obesity Compound Library owns a unique collection of 2,411 compounds, which mainly target signaling pathway of controlling appetite, fatty acid metabolism and energy expenditure, etc. This library is a useful tool for discovery anti-obesity drugs.

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-W153897

N-Methyltyramine	Structural Classification Alkaloids Human Gut Microbiota Metabolites Microorganisms Leguminosae Other Alkaloids Source classification Acacia auriculiformis A.Cunn. ex Benth Plants Endogenous metabolite	Adrenergic Receptor
N-Methyltyramine is a protoalkaloid that can be isolated from various plant species. N-Methyltyramine is an α2-adrenoreceptor antagonist. N-Methyltyramine enhances appetite and digestion of foods by stimulating gastrin and pancreatic secretions. N-Methyltyramine can relax mouse small intestinal smooth muscle and inhibits small intestinal propulsion .

HY-N7503

Psoralenoside	Infection Structural Classification Classification of Application Fields Simple Phenylpropanols Leguminosae Source classification Metabolic Disease Phenylpropanoids Psoralea corylifolia L. Plants Disease Research Fields	Histamine Receptor Calcium Channel Calmodulin
Psoralenoside is a benzofuran glycoside from Psoralea corylifolia . Psoralenoside exhibits high binding affinities against histaminergic H₁, calmodulin, and voltage-gated L-type calcium channels (E-value≥-6.5 Kcal/mol) . Psoralenoside shows estrogen-like activity, osteoblastic proliferation accelerating activity, antitumor effects and antibacterial activity .

HY-N0584B

Anisodamine hydrochloride 6-Hydroxyhyoscyamine hydrochloride	Structural Classification Alkaloids Pyrrole Alkaloids Anisodus tanguticus (Maxinowicz) Pascher Source classification Plants Solanaceae	Adrenergic Receptor
Anisodamine hydrochloride is an anticholinergic and α1 adrenergic receptor antagonist. Anisodamine hydrochloride can be used for improving blood flow in circulatory disorders such as septic shock, Anisodamine hydrochloride displays a spectrum of pharmacological effects similar to Atropine (HY-B1205) and Sopolamine (HY-B2065) including inhibition of salivation, gastrointestinal and sweat secretion, gastrointestinal motility, respiratory secretion and urinary bladder contraction in vivo .

Cat. No.	Product Name	Chemical Structure

HY-B0113S

Omeprazole-d₃
Omeprazole-d₃ is deuterium labeled Omeprazole. Omeprazole, a proton pump inhibitor (PPI), is available for treatment of acid-related gastrointestinal disorders. Omeprazole shows competitive inhibition of CYP2C19 activity with a Ki of 2 to 6 μM[1]. Omeprazole also inhibits growth of Gram-positive and Gram-negative bacteria[2].

HY-B0113S1

Omeprazole-d3-1

Omeprazole-d₃-1 is the deuterium labeled Omeprazole. Omeprazole (H 16868), a proton pump inhibitor (PPI), is available for treatment of acid-related gastrointestinal disorders. Omeprazole shows competitive inhibition of CYP2C19 activity with a Ki of 2 to 6 μM[1]. Omeprazole also inhibits growth of Gram-positive and Gram-negative bacteria[2].Omeprazole is a potent brain penetrant neutral sphingomyelinase (N-SMase) inhibitor (exosome inhibitor)[3].

HY-B0113S3

Omeprazole-13CD3

Omeprazole- ¹³C,d₃ is a ¹³C-labeled and deuterium labeled Omeprazole. Omeprazole (H 16868), a proton pump inhibitor (PPI), is available for treatment of acid-related gastrointestinal disorders. Omeprazole shows competitive inhibition of CYP2C19 activity with a Ki of 2 to 6 μM[1]. Omeprazole also inhibits growth of Gram-positive and Gram-negative bacteria[2].Omeprazole is a potent brain penetrant neutral sphingomyelinase (N-SMase) inhibitor (exosome inhibitor)[3].

HY-N6948S

Linalyl acetate-d6

Linalyl acetate-d₆ is deuterated labeled Omeprazole (HY-B0113). Omeprazole (H 16868), a proton pump inhibitor (PPI), is available for treatment of acid-related gastrointestinal disorders. Omeprazole shows competitive inhibition of CYP2C19 activity with a K_i of 2 to 6 μM . Omeprazole also inhibits growth of Gram-positive and Gram-negative bacteria .Omeprazole is a potent brain penetrant neutral sphingomyelinase (N-SMase) inhibitor (exosome inhibitor) .

HY-B0113S4

Omeprazole-d3 sodium

Omeprazole-d₃ sodium is deuterated labeled Omeprazole (HY-B0113). Omeprazole (H 16868), a proton pump inhibitor (PPI), is available for treatment of acid-related gastrointestinal disorders. Omeprazole shows competitive inhibition of CYP2C19 activity with a K_i of 2 to 6 μM . Omeprazole also inhibits growth of Gram-positive and Gram-negative bacteria .Omeprazole is a potent brain penetrant neutral sphingomyelinase (N-SMase) inhibitor (exosome inhibitor) .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks